Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
28.00
+1.15 (4.28%)
At close: Dec 10, 2025, 4:00 PM EST
28.11
+0.11 (0.39%)
After-hours: Dec 10, 2025, 7:56 PM EST
Agios Pharmaceuticals Employees
As of December 31, 2024, Agios Pharmaceuticals had 488 total employees, including 486 full-time and 2 part-time employees. The number of employees increased by 102 or 26.42% compared to the previous year.
Employees
488
Change (1Y)
102
Growth (1Y)
26.42%
Revenue / Employee
$91,785
Profits / Employee
-$822,264
Market Cap
1.63B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 488 | 102 | 26.42% |
| Dec 31, 2023 | 386 | -7 | -1.78% |
| Dec 31, 2022 | 393 | 1 | 0.26% |
| Dec 31, 2021 | 392 | -170 | -30.25% |
| Dec 31, 2020 | 562 | 26 | 4.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AGIO News
- 2 days ago - Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - GlobeNewsWire
- 21 days ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript - Seeking Alpha
- 21 days ago - Why Shares in Agios Pharmaceuticals Got Crushed Today - The Motley Fool
- 21 days ago - Why Is Agios Pharmaceuticals Stock Sinking Today? - Benzinga
- 21 days ago - Agios Pharma reports mixed results in late-stage study for sickle cell disease drug - Reuters
- 21 days ago - Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease - GlobeNewsWire
- 5 weeks ago - Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones - Seeking Alpha
- 5 weeks ago - Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition - GlobeNewsWire